Skip to main content
ConductScienceScienceDex

Stacey Lynn Clardy

From the FY2025 NIH awards this investigator leads as contact PI. The department is the award's.

FY2025 NIH rank #2,565
Unclaimed recordClaim profile
  • Program Leader
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 11964061Search this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Neurology

NIH Funding · FY2025

Linked Award Amount
$3.5M
Full award amounts, FY2025
Award Records
2
Records listing this PI
Award-Linked Rank
#2,565
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Stacey Lynn Clardy. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2025 award records by amount

NIH award records listing Stacey Lynn Clardy as a PI. Multi-PI records show the full award amount for context.

  • 5U01NS120901-04U01Contact PI
    A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease
    University of Utah · Neurology (NIH department code)
    $3.5M
    award amount
  • 3U01NS120901-04S1U01Contact PI
    A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease
    University of Utah · Neurology (NIH department code)
    $50.5K
    award amount

Award organization

Organizations that administered FY2025 awards listing Stacey Lynn Clardy as a PI.

FY2025 award administered by University of Utah (UT).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    University of Utah
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #1897
  6. 2024
    Entered Top 25% Nationally
    Ranked #1897
  7. 2024
    Entered Top 10% Nationally
    Ranked #1897
  8. 2025
    $5M Cumulative Funding
  9. 2025
    Program/Center Grant Leader
  10. 2026
    $10M Cumulative Funding

Explore further

Find collaborators for Stacey Lynn Clardy

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →